Amgen, GSK Join To Market Novel Osteo Drug In China, India, S. Korea

Two multinational drug makers plan to market a new type of treatment for osteoporosis around the globe, including China, India and South Korea. U.K.-based GlaxoSmithKline is to handle marketing duties in those countries because the drug's maker, U.S.-based Amgen, does not have a presence in them. The drug is denosumab, intended to be injected only twice a year to handle the disease. It also is expected to be a blockbuster drug. (Click here for more